Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$71.98
+1.2%
$68.94
$60.56
$82.49
$8.66B0.861.71 million shs3.33 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$126.55
-0.6%
$115.84
$84.23
$157.98
$12.60B0.241.15 million shs1.58 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.33
$19.45
$31.79
$2.77B0.731.26 million shsN/A
Repligen Corporation stock logo
RGEN
Repligen
$118.85
+1.1%
$128.71
$102.97
$182.52
$6.60B1.1734,224 shs770,906 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.00%+0.07%-2.73%+2.51%+4.17%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+1.84%+3.54%+13.75%-2.71%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%0.00%+0.55%+23.44%
Repligen Corporation stock logo
RGEN
Repligen
0.00%-10.48%-7.88%-16.05%-4.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Henry Schein, Inc. stock logo
HSIC
Henry Schein
3.4384 of 5 stars
2.31.00.03.42.21.71.9
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.7538 of 5 stars
4.43.00.02.92.62.51.9
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.3259 of 5 stars
1.00.02.51.70.01.72.5
Repligen Corporation stock logo
RGEN
Repligen
4.6477 of 5 stars
4.31.00.04.52.91.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.64
Moderate Buy$79.3010.17% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.86
Moderate Buy$162.0028.01% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$173.2545.77% Upside

Current Analyst Ratings Breakdown

Latest HSIC, PDCO, NBIX, and RGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$145.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $75.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$90.00 ➝ $86.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$137.00 ➝ $152.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$96.00 ➝ $115.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$155.00 ➝ $165.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$138.00 ➝ $139.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$158.00 ➝ $160.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.69$7.42 per share9.70$32.33 per share2.23
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.36B5.32$3.36 per share37.67$25.58 per share4.95
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
Repligen Corporation stock logo
RGEN
Repligen
$634.44M10.52$3.14 per share37.83$35.21 per share3.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$390M$3.2022.4914.342.293.21%14.87%5.82%8/5/2025 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$341.30M$2.9542.9019.561.3112.68%11.81%8.59%7/30/2025 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%8/26/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A50.363.37-3.93%4.53%3.17%7/29/2025 (Estimated)

Latest HSIC, PDCO, NBIX, and RGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.11$1.15+$0.04$0.88$3.24 billion$3.17 billion
5/5/2025Q1 2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$0.70$0.08-$0.62$0.08$587.06 million$572.60 million
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.50
1.38
0.75
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
3.13
3.02
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79

Institutional Ownership

CompanyInstitutional Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%
Repligen Corporation stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.08%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.80%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.90%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000121.72 million120.41 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
1,80098.97 million94.22 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$71.98 +0.85 (+1.19%)
Closing price 04:00 PM Eastern
Extended Trading
$71.98 +0.00 (+0.01%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$126.55 -0.76 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$127.32 +0.77 (+0.61%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

$31.33 0.00 (0.00%)
As of 04/17/2025

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.

Repligen stock logo

Repligen NASDAQ:RGEN

$118.85 +1.31 (+1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$118.84 0.00 (0.00%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.